These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 22585002)

  • 1. Targeting ALK in neuroblastoma--preclinical and clinical advancements.
    Carpenter EL; Mossé YP
    Nat Rev Clin Oncol; 2012 May; 9(7):391-9. PubMed ID: 22585002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma.
    Bresler SC; Wood AC; Haglund EA; Courtright J; Belcastro LT; Plegaria JS; Cole K; Toporovskaya Y; Zhao H; Carpenter EL; Christensen JG; Maris JM; Lemmon MA; Mossé YP
    Sci Transl Med; 2011 Nov; 3(108):108ra114. PubMed ID: 22072639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anaplastic Lymphoma Kinase as a Cancer Target in Pediatric Malignancies.
    Mossé YP
    Clin Cancer Res; 2016 Feb; 22(3):546-52. PubMed ID: 26503946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody targeting of anaplastic lymphoma kinase induces cytotoxicity of human neuroblastoma.
    Carpenter EL; Haglund EA; Mace EM; Deng D; Martinez D; Wood AC; Chow AK; Weiser DA; Belcastro LT; Winter C; Bresler SC; Vigny M; Mazot P; Asgharzadeh S; Seeger RC; Zhao H; Guo R; Christensen JG; Orange JS; Pawel BR; Lemmon MA; Mossé YP
    Oncogene; 2012 Nov; 31(46):4859-67. PubMed ID: 22266870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MEK inhibitor trametinib does not prevent the growth of anaplastic lymphoma kinase (ALK)-addicted neuroblastomas.
    Umapathy G; Guan J; Gustafsson DE; Javanmardi N; Cervantes-Madrid D; Djos A; Martinsson T; Palmer RH; Hallberg B
    Sci Signal; 2017 Nov; 10(507):. PubMed ID: 29184034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of Axl improves the targeted therapy against ALK-mutated neuroblastoma.
    Xu F; Li H; Sun Y
    Biochem Biophys Res Commun; 2014 Nov; 454(4):566-71. PubMed ID: 25450694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anaplastic lymphoma kinase as a therapeutic target in anaplastic large cell lymphoma, non-small cell lung cancer and neuroblastoma.
    Cheng M; Ott GR
    Anticancer Agents Med Chem; 2010 Mar; 10(3):236-49. PubMed ID: 20406193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting ALK: a promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin's lymphoma, and neuroblastoma.
    Morales La Madrid A; Campbell N; Smith S; Cohn SL; Salgia R
    Target Oncol; 2012 Sep; 7(3):199-210. PubMed ID: 22968692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers.
    Cheng M; Quail MR; Gingrich DE; Ott GR; Lu L; Wan W; Albom MS; Angeles TS; Aimone LD; Cristofani F; Machiorlatti R; Abele C; Ator MA; Dorsey BD; Inghirami G; Ruggeri BA
    Mol Cancer Ther; 2012 Mar; 11(3):670-9. PubMed ID: 22203728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma.
    Infarinato NR; Park JH; Krytska K; Ryles HT; Sano R; Szigety KM; Li Y; Zou HY; Lee NV; Smeal T; Lemmon MA; Mossé YP
    Cancer Discov; 2016 Jan; 6(1):96-107. PubMed ID: 26554404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exceptional response to the ALK and ROS1 inhibitor lorlatinib and subsequent mechanism of resistance in relapsed
    Liu T; Merguerian MD; Rowe SP; Pratilas CA; Chen AR; Ladle BH
    Cold Spring Harb Mol Case Stud; 2021 Aug; 7(4):. PubMed ID: 34210658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting anaplastic lymphoma kinase in neuroblastoma.
    Umapathy G; Mendoza-Garcia P; Hallberg B; Palmer RH
    APMIS; 2019 May; 127(5):288-302. PubMed ID: 30803032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted Therapy for Neuroblastoma: ALK Inhibitors.
    Schulte JH; Schulte S; Heukamp LC; Astrahantseff K; Stephan H; Fischer M; Schramm A; Eggert A
    Klin Padiatr; 2013 Nov; 225(6):303-8. PubMed ID: 24166094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma.
    Bresler SC; Weiser DA; Huwe PJ; Park JH; Krytska K; Ryles H; Laudenslager M; Rappaport EF; Wood AC; McGrady PW; Hogarty MD; London WB; Radhakrishnan R; Lemmon MA; Mossé YP
    Cancer Cell; 2014 Nov; 26(5):682-94. PubMed ID: 25517749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The second-generation ALK inhibitor alectinib effectively induces apoptosis in human neuroblastoma cells and inhibits tumor growth in a TH-MYCN transgenic neuroblastoma mouse model.
    Lu J; Guan S; Zhao Y; Yu Y; Woodfield SE; Zhang H; Yang KL; Bieerkehazhi S; Qi L; Li X; Gu J; Xu X; Jin J; Muscal JA; Yang T; Xu GT; Yang J
    Cancer Lett; 2017 Aug; 400():61-68. PubMed ID: 28455243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The R1275Q neuroblastoma mutant and certain ATP-competitive inhibitors stabilize alternative activation loop conformations of anaplastic lymphoma kinase.
    Epstein LF; Chen H; Emkey R; Whittington DA
    J Biol Chem; 2012 Oct; 287(44):37447-57. PubMed ID: 22932897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ALK inhibitors in the treatment of advanced NSCLC.
    Gridelli C; Peters S; Sgambato A; Casaluce F; Adjei AA; Ciardiello F
    Cancer Treat Rev; 2014 Mar; 40(2):300-6. PubMed ID: 23931927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors.
    McDermott U; Iafrate AJ; Gray NS; Shioda T; Classon M; Maheswaran S; Zhou W; Choi HG; Smith SL; Dowell L; Ulkus LE; Kuhlmann G; Greninger P; Christensen JG; Haber DA; Settleman J
    Cancer Res; 2008 May; 68(9):3389-95. PubMed ID: 18451166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunoassays for the quantification of ALK and phosphorylated ALK support the evaluation of on-target ALK inhibitors in neuroblastoma.
    Tucker ER; Tall JR; Danielson LS; Gowan S; Jamin Y; Robinson SP; Banerji U; Chesler L
    Mol Oncol; 2017 Aug; 11(8):996-1006. PubMed ID: 28432815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anaplastic lymphoma kinase (ALK) inhibitor response in neuroblastoma is highly correlated with ALK mutation status, ALK mRNA and protein levels.
    Duijkers FA; Gaal J; Meijerink JP; Admiraal P; Pieters R; de Krijger RR; van Noesel MM
    Cell Oncol (Dordr); 2011 Oct; 34(5):409-17. PubMed ID: 21625996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.